Reumatologia Clinica最新文献

{"title":"Actualización de las Guías para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de Reumatología 2023","authors":"Carlos Abud-Mendoza ,&nbsp;Francisco Javier Aceves-Ávila ,&nbsp;César Alejandro Arce-Salinas ,&nbsp;José Álvarez Nemegyei ,&nbsp;Leonor Barile-Fabris ,&nbsp;Sergio Durán-Barragán ,&nbsp;Diana Elsa Flores-Alvarado ,&nbsp;Eufrates Hernández-Núñez ,&nbsp;Fedra Irazoque-Palazuelos ,&nbsp;José Francisco Moctezuma-Ríos ,&nbsp;Virginia Pascual-Ramos ,&nbsp;Margarita Portela-Hernández ,&nbsp;Luis Humberto Silveira ,&nbsp;Lilia Andrade-Ortega ,&nbsp;Ana Barrera-Vargas ,&nbsp;Sandra Carrillo-Vázquez ,&nbsp;Zully Castro-Colin ,&nbsp;Enrique Cuevas-Orta ,&nbsp;Luis Felipe Flores-Suárez ,&nbsp;Guillermo Arturo Guaracha-Basáñez ,&nbsp;César Pacheco-Tena","doi":"10.1016/j.reuma.2024.02.002","DOIUrl":"10.1016/j.reuma.2024.02.002","url":null,"abstract":"<div><h3>Objective</h3><p>To develop updated guidelines for the pharmacological management of rheumatoid arthritis (RA).</p></div><div><h3>Methods</h3><p>A group of experts representative of different geographical regions and various medical services catering to the Mexican population with RA was formed. Questions based on Population, Intervention, Comparison, and Outcome (PICO) were developed, deemed clinically relevant. These questions were answered based on the results of a recent systematic literature review (SLR), and the evidence's validity was assessed using the GRADE system, considered a standard for these purposes. Subsequently, the expert group reached consensus on the direction and strength of recommendations through a multi-stage voting process.</p></div><div><h3>Results</h3><p>The updated guidelines for RA treatment stratify various therapeutic options, including different classes of DMARDs (conventional, biologicals, and JAK inhibitors), as well as NSAIDs, glucocorticoids, and analgesics. By consensus, it establishes the use of these in different subpopulations of interest among RA patients and addresses aspects related to vaccination, COVID-19, surgery, pregnancy and lactation, and others.</p></div><div><h3>Conclusions</h3><p>This update of the Mexican guidelines for the pharmacological treatment of RA provides reference points for evidence-based decision-making, recommending patient participation in joint decision-making to achieve the greatest benefit for our patients. It also establishes recommendations for managing a variety of relevant conditions affecting our patients.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140764337","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pósteres: P200-P299","authors":"","doi":"10.1016/S1699-258X(24)00063-9","DOIUrl":"https://doi.org/10.1016/S1699-258X(24)00063-9","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Junta Directiva de la SER, Comité de Organización de Congresos, Comité Científico del Congreso y Comité Organizador Local del Congreso","authors":"","doi":"10.1016/S1699-258X(24)00058-5","DOIUrl":"https://doi.org/10.1016/S1699-258X(24)00058-5","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S1699258X24000585/pdfft?md5=b7d147f2f3cb7a2fca4d8730541b13f1&pid=1-s2.0-S1699258X24000585-main.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141095518","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Escorbuto. Una pseudovasculitis olvidada","authors":"Noelia Cabaleiro-Raña ,&nbsp;Diego Santos-Álvarez ,&nbsp;Lucía Romar de las Heras ,&nbsp;Carmen Álvarez-Reguera ,&nbsp;Evelin Cecilia Cervantes Pérez ,&nbsp;Rosa María Hernández Cancela ,&nbsp;Susana Romero-Yuste","doi":"10.1016/j.reuma.2024.01.001","DOIUrl":"10.1016/j.reuma.2024.01.001","url":null,"abstract":"<div><p>Scurvy is a nutritional disease caused by ascorbic acid (vitamin C) deficiency. Althought currently it is a rare disease, we should considerer it in the differential diagnosis of purpura and arthritis in patients with restrictive diets.</p><p>We present the case of a 49-year-old man with a history of a nutritional disorder presented to our hospital with generalized purpura and hemarthros. Following the anamnesis and laboratory findings, rheumatological, infectious and hematological etiologies were excluded. Finally, the diagnosis of scurvy was made upon demostration poor levels of vitamin C and a spectacular response to nutritional supplements. We compare this case with 19 similar cases reported in the medical literature.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140466168","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pósteres: P300-P399","authors":"","doi":"10.1016/S1699-258X(24)00064-0","DOIUrl":"https://doi.org/10.1016/S1699-258X(24)00064-0","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094896","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trabajos aceptados solo para publicación","authors":"","doi":"10.1016/S1699-258X(24)00060-3","DOIUrl":"https://doi.org/10.1016/S1699-258X(24)00060-3","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141094892","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Cardiopulmonary phenotype in systemic sclerosis associated pulmonary hypertension","authors":"Luis Javier Cajas Santana ,&nbsp;Alejandro Correa Giraldo ,&nbsp;Maria Carolina Torres","doi":"10.1016/j.reuma.2024.01.004","DOIUrl":"10.1016/j.reuma.2024.01.004","url":null,"abstract":"<div><h3>Introduction</h3><p>Pulmonary hypertension (PH) associated with systemic sclerosis (SSc) increases morbidity and mortality. Cardiopulmonary comorbidities, as per the 2021 PH consensus, play a role in the choice of therapy between monotherapy and combination therapy.</p></div><div><h3>Methods</h3><p>A cross-sectional study was conducted in patients with SSc based on the 2013 ACR/EULAR criteria or very early disease (VEDOSS 2011). PH was considered if they met the following criteria: pulmonary artery systolic pressure (PASP)<!--> <!-->&gt;<!--> <!-->39<!--> <!-->mmHg or peak tricuspid regurgitation velocity (PTRV)<!--> <!-->&gt;<!--> <!-->3.4<!--> <!-->m/s, PASP between 33 and 39<!--> <!-->mmHg or PTRV between 2.9 and 3.4<!--> <!-->m/s plus two additional findings suggestive of PH. PH was classified as type 2 if LVEF<!--> <!-->&lt;<!--> <!-->50% or moderate to severe diastolic dysfunction was present; type 3 if extensive interstitial disease on tomography<!--> <!-->&gt;<!--> <!-->20% or forced vital capacity (FVC)<!--> <!-->&lt;<!--> <!-->75%; type 4 if abnormalities related to embolism were detected on scintigraphy or tomography. If patients did not meet these criteria, they were classified as type 1 PH. Complete data on cardiopulmonary risk factors and other factors were required. The frequency of these factors in the population and differences between groups based on risk factors were estimated.</p></div><div><h3>Results</h3><p>A total of 228 patients were selected. Three had type 2 PH, 24 had type 3, and 40 had type 1 PH, with the majority (75%) having at least one cardiopulmonary risk factor, and 47.5% having more than one. Mild diastolic dysfunction (25%) and hypertension (35%) were the most prevalent. In the type 1 PH group, those with risk factors experienced an increase in the number of years with Raynaud's phenomenon, anticentromere antibodies, and gastrointestinal symptoms (<em>p</em> <!-->&lt;<!--> <!-->0.05).</p></div><div><h3>Conclusion</h3><p>In patients with PH, 75% have one, and 45% have two or more risk factors.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140089151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"From clots to cuts in antiphospholipid syndrome","authors":"Abihai Lucas Hernández ,&nbsp;Yehuda Shoenfeld","doi":"10.1016/j.reuma.2023.10.005","DOIUrl":"https://doi.org/10.1016/j.reuma.2023.10.005","url":null,"abstract":"","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140824105","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Consenso Delphi sobre el uso de la telemedicina en reumatología: estudio RESULTAR","authors":"Jenaro Graña Gil ,&nbsp;María José Moreno Martínez ,&nbsp;María del Carmen Carrasco Cubero","doi":"10.1016/j.reuma.2024.01.005","DOIUrl":"10.1016/j.reuma.2024.01.005","url":null,"abstract":"<div><h3>Background and objectives</h3><p>There is growing interest in the potential of telemedicine (TM) as an alternative to physical consultation. Although numerous studies prove the benefits of TM in rheumatology, there are no recommendations on its implementation in Spain. The aim of this study was to analyze the application of TM in rheumatology consultations in Spain.</p></div><div><h3>Materials and methods</h3><p>Qualitative, cross-sectional, multicenter study with Delphi methodology in 2 rounds of queries. A structured ad hoc questionnaire was designed that included statements on teleconsultation, nursing teleconsultation, telecare, telerehabilitation, teleradiology, telehealth tele-education, main barriers, advantages and disadvantages of telehealth tele-education and TM in rheumatoid arthritis. The participants were rheumatology specialists practicing in Spain.</p></div><div><h3>Results</h3><p>The participating rheumatologists (N<!--> <!-->=<!--> <!-->80) had a mean age of 42.4 (±<!--> <!-->9.0) years, with 12.6 (±<!--> <!-->8.4) years of experience. Some of the aspects of TM that obtained the greatest consensus were: TM is useful for follow-up of some patients, to help determine if a face-to-face consultation is necessary, or to assist patients with rheumatoid arthritis if they present low activity or in remission; certain patients, such as those in their first consultation or those who present digital barriers or cognitive deterioration, should be seen face-to-face; TM presents some technical and patient access barriers; TM can be useful in nursing and in continued medical education.</p></div><div><h3>Conclusions</h3><p>TM can be beneficial for the treatment and follow-up of patients with rheumatic diseases, as well as for alleviating the face-to-face care burden in rheumatology.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140462375","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Prevalence of polypharmacy and drug interaction in older adults with rheumatic disease","authors":"Rodrigo Lozano-Lozano ,&nbsp;David Vega-Morales ,&nbsp;Macarena del Rosario Sifuentes-Martinez ,&nbsp;Denisse Ornelas-Balcazar","doi":"10.1016/j.reuma.2024.02.006","DOIUrl":"10.1016/j.reuma.2024.02.006","url":null,"abstract":"<div><h3>Introduction/Aim</h3><p>Older people with rheumatic diseases tend to have a greater number of associated comorbidities, which will require the use of more drugs, increasing the risk of hospitalizations, complications, and drug interactions. In Mexico, there has been an estimated prevalence of polypharmacy of up to 55%, however there are scarce reports on the topic in our elderly population with rheumatic diseases. We aimed to determine the prevalence of polypharmacy and the association of drug interactions in patients treated for rheumatic disease.</p></div><div><h3>Methods</h3><p>A retrospective observational study was conducted on patients undergoing treatment for rheumatic diseases who were treated in geriatrics and rheumatology clinics from January to December 2021. The presence of polypharmacy and drug interactions was evaluated using the BOT Plus Pharmacological Surveillance System. The prevalence of polypharmacy and the association of drug interactions were estimated.</p></div><div><h3>Results</h3><p>We evaluated 320 patients, with a mean age of 67.05<!--> <!-->±<!--> <!-->5.8 years, predominantly female (85%). The prevalence of polypharmacy was 68.1% (<em>n</em> <!-->=<!--> <!-->218), of which 214 (98.1%) patients had related drug interactions; 27.1% were severe and 53.2% as moderate interactions. Factors related with increased risk of drug interactions were being exposed to hypertension increased the risk of drug interactions (POR 1.75, 95% CI 1.44–2.14; <em>P</em> <!-->&lt;<!--> <!-->0.001), having osteoarthritis (POR 1.21, 95% CI 1.04–1.42; <em>P</em> <!-->=<!--> <!-->0.032) and thyroid disease (POR 1.45, 95% CI 1.28–1.65; <em>P</em> <!-->=<!--> <!-->0.001). The most prevalent serious interactions were leflunomide–methotrexate in 27 (46.5%) patients and buprenorphine–tramadol in 8 (13.7%).</p></div><div><h3>Conclusions</h3><p>A high prevalence of polypharmacy and drug interactions was observed in elderly patients with rheumatic diseases. The main associated factors were comorbidities, particularly high blood pressure, osteoarthritis and thyroid diseases.</p></div>","PeriodicalId":47115,"journal":{"name":"Reumatologia Clinica","volume":null,"pages":null},"PeriodicalIF":1.5,"publicationDate":"2024-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140760215","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}